Latest China Market Entry News

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Wide Open Agriculture has made significant strides in expanding its intellectual property and commercial footprint, including a new patent for lupin protein milk and first sales of lupin oil, while progressing plans for a large-scale manufacturing facility in Western Australia.

AuMake Limited reports positive operating cashflow and a strategic pivot into China’s high-growth OTC medicine market, supported by a $1.5 million capital raise and significant governance reforms.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.

Merino & Co. has secured a significant follow-up order from its Shanghai-based omni-channel distributor, reinforcing its expanding footprint in China’s retail and digital markets.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Merino & Co. initiates a new chapter with leadership changes and a strategic partnership to enter China’s premium apparel market, while investing heavily in growth during Q1 FY26.

Nova Eye Medical reported a robust 32% increase in global sales excluding China for Q1 FY26 and secured regulatory approval for its iTrack™ Advance device in China, setting the stage for expanded market penetration.

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.